Health care stocks advanced late Friday afternoon, with the NYSE Health Care Index rising 1.8% and the Health Care Select Sector SPDR Fund (XLV) adding 1.5%.
The iShares Biotechnology ETF (IBB) climbed 1.5%.
In corporate news, DexCom (DXCM) shares jumped past 16%. The company late Thursday maintained its full-year revenue guidance after delivering a Q1 sales beat.
BrightSpring Health Services (BTSG) shares surged more than 16% after it reported Q1 adjusted EPS and revenue above analyst expectations and raised its 2025 revenue guidance.
Cytokinetics (CYTK) shares fell 12% after the US Food and Drug Administration extended the Prescription Drug User Fee Act action date to Dec. 26 for aficamten in obstructive hypertrophic cardiomyopathy in the previous day.
Novo Nordisk (NVO) shares popped 5.7% after Health Canada accepted for review a supplemental new drug submission for semaglutide 2.4 mg as a once weekly treatment for people with metabolic dysfunction-associated steatohepatitis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.